Antagonistic anti-hTNFSF13b human antibodies
US7317089B2 · kind B2 · utility
29Cited by
3References
3Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 15, 2002 |
| Grant date | Jan 8, 2008 |
| Priority date | — |
| Expiry date | Dec 16, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b(e.g., KD=10−8 M or less), a slow off rate for TNFSF13b dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize TNFSF13b activity in vitro and in vivo. The antibodies of the invention are useful in one embodiment for inhibiting TNFSF13b activity in a human subject suffering from a disorder in which hTNFSF13b activity is detrimental. Nucleic acids encoding the antibodies of the present invention, as well as, vectors and host cells for expressing them are also encompassed by the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.